Makani Science vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 57)
Makani Science logo

Makani Science

ChallengerHealthcare

General

Agricultural computational biology startup applying machine learning to plant science; accelerating crop improvement research for disease resistance, drought tolerance, and yield optimization.

AI VisibilityBeta
Overall Score
C57
Category Rank
#146 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
55
Perplexity
59
Gemini
57

About

Makani Science is an agricultural biotechnology company applying computational biology and machine learning to plant science research — developing data-driven approaches to accelerate crop improvement, understand plant-pathogen interactions, and optimize agricultural inputs for yield and sustainability outcomes. Founded in 2021 and headquartered in San Francisco, Makani Science operates at the intersection of data science, genomics, and plant biology to address fundamental agricultural productivity challenges.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

57
Overall Score
90
#146
Category Rank
#2
86
AI Consensus
83
stable
Trend
stable
55
ChatGPT
92
59
Perplexity
93
57
Gemini
89
54
Claude
96
59
Grok
95

Key Details

Category
General
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.